Bioarray Genetics

bioarray.us

Bioarray Genetics is a biotech company located in New Haven, Connecticut. We are committed to transforming cancer treatment decisions and outcomes using gene profiling to provide clinically actionable results to clinicians and patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

ELEMENT BIOSCIENCES BECOMES THE NEWEST MEMBER OF 10X GENOMICS’ COMPATIBLE PARTNER PROGRAM (CPP) ACROSS MULTIPLE SINGLE CELL APPLICATIONS

Element Biosciences, Inc. | March 01, 2022

news image

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single cell technologies. 10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, che...

Read More

RESEARCH

KINETA AND SAMSUNG BIOLOGICS ANNOUNCE ANTI-VISTA ANTIBODY IMMUNOTHERAPY DEVELOPMENT AND MANUFACTURING AGREEMENT

Samsung Biologics | July 21, 2021

news image

Kineta, Inc., a clinical-stage biotech firm developing novel immunotherapies in oncology, has signed a strategic partnership agreement with Samsung Biologics, one of the world's top contract development and manufacturing companies (CDMO). To support the IND filing for KVA12.1, Kineta's new anti-VISTA antibody under development to treat solid tumors, Samsung Biologics will offer end-through-end CDMO services ranging from cell line development to cell line development clinical drug substan...

Read More

INDUSTRIAL IMPACT

PERSEPHONE BIOSCIENCES CLOSES $15M SEED FINANCING ROUND

Persephone Biosciences | July 20, 2022

news image

Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health through the development of microbiome-based medicines, today announced that it has closed a $15 million seed financing round. The round was co-led by First Bight Ventures and Propel Bio Partners, and included investments from Y Combinator, Fifty Years, Susa Ventures, American Cancer Society’s BrightEdge Fund, Pioneer Fund, and ZhenFund among others. “Thi...

Read More

INDUSTRIAL IMPACT

SKYLINEDX RAISES NEW CAPITAL FROM NOVALIS LIFESCIENCES AND VAN HERK INVESTMENTS

SkylineDx | December 22, 2021

news image

SkylineDx announced it received a capital investment from USA based investment and advisory firm Novalis LifeSciences, and one of Benelux' largest biotech investors Van Herk Investments, to further solidify its position in the USA dermatology diagnostics market. SkylineDx is at a critical growth stage in their development now that the first products are introduced to the USA market, and Novalis LifeSciences has demonstrated impressive successes with their strategic and operational advi...

Read More
news image

INDUSTRIAL IMPACT

ELEMENT BIOSCIENCES BECOMES THE NEWEST MEMBER OF 10X GENOMICS’ COMPATIBLE PARTNER PROGRAM (CPP) ACROSS MULTIPLE SINGLE CELL APPLICATIONS

Element Biosciences, Inc. | March 01, 2022

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single cell technologies. 10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, che...

Read More
news image

RESEARCH

KINETA AND SAMSUNG BIOLOGICS ANNOUNCE ANTI-VISTA ANTIBODY IMMUNOTHERAPY DEVELOPMENT AND MANUFACTURING AGREEMENT

Samsung Biologics | July 21, 2021

Kineta, Inc., a clinical-stage biotech firm developing novel immunotherapies in oncology, has signed a strategic partnership agreement with Samsung Biologics, one of the world's top contract development and manufacturing companies (CDMO). To support the IND filing for KVA12.1, Kineta's new anti-VISTA antibody under development to treat solid tumors, Samsung Biologics will offer end-through-end CDMO services ranging from cell line development to cell line development clinical drug substan...

Read More
news image

INDUSTRIAL IMPACT

PERSEPHONE BIOSCIENCES CLOSES $15M SEED FINANCING ROUND

Persephone Biosciences | July 20, 2022

Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health through the development of microbiome-based medicines, today announced that it has closed a $15 million seed financing round. The round was co-led by First Bight Ventures and Propel Bio Partners, and included investments from Y Combinator, Fifty Years, Susa Ventures, American Cancer Society’s BrightEdge Fund, Pioneer Fund, and ZhenFund among others. “Thi...

Read More
news image

INDUSTRIAL IMPACT

SKYLINEDX RAISES NEW CAPITAL FROM NOVALIS LIFESCIENCES AND VAN HERK INVESTMENTS

SkylineDx | December 22, 2021

SkylineDx announced it received a capital investment from USA based investment and advisory firm Novalis LifeSciences, and one of Benelux' largest biotech investors Van Herk Investments, to further solidify its position in the USA dermatology diagnostics market. SkylineDx is at a critical growth stage in their development now that the first products are introduced to the USA market, and Novalis LifeSciences has demonstrated impressive successes with their strategic and operational advi...

Read More